Literature DB >> 15983047

Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 loop library.

Keisuke Yusa1, Yosuke Maeda, Aki Fujioka, Kazuaki Monde, Shinji Harada.   

Abstract

The human immunodeficiency virus (HIV-1) envelope glycoprotein (GP) 120 interacts with CD4 and the CCR5 coreceptor for viral entry. The V3 loop in GP120 is a crucial region for determining coreceptor usage during viral entry, and a variety of amino acid substitutions has been observed in clinical isolates. To construct an HIV-1 V3 loop library, we chose 10 amino acid positions in the V3 loop and incorporated random combinations (27,648 possibilities) of the amino acid substitutions derived from 31 R5 viruses into the V3 loop of HIV-1(JR-FL) proviral DNA. The constructed HIV-1 library contained 6.6 x 10(6) independent clones containing a set of 0-10 amino acid substitutions in the V3 loop. To address whether restricted steric alteration in the V3 loop could confer resistance to an entry inhibitor, TAK-779, we selected entry inhibitor-resistant HIV-1 by increasing the concentration of TAK-779 from 0.10 to 0.30 microM in PM1-CCR5 cells with high expression of CCR5. The selected viruses at passage 8 contained five amino acid substitutions in the V3 loop without any other mutations in GP120 and showed 15-fold resistance compared with the parental virus. These results indicated that a certain structure of the V3 loop containing amino acid substitutions derived from 31 R5 viruses can contribute to the acquisition of resistance to entry inhibitors binding to CCR5. Taken together, this type of HIV-1 V3 loop library is useful for isolating and analyzing the specific biological features of HIV-1 with respect to alterations of the V3 loop structure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15983047     DOI: 10.1074/jbc.M414360200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  15 in total

1.  Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.

Authors:  Timothy J Henrich; Nicolas R P Lewine; Sun-Hee Lee; Suhas S P Rao; Reem Berro; Roy M Gulick; John P Moore; Athe M N Tsibris; Daniel R Kuritzkes
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

2.  Enhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds.

Authors:  Kazuhisa Yoshimura; Shigeyoshi Harada; Junji Shibata; Makiko Hatada; Yuko Yamada; Chihiro Ochiai; Hirokazu Tamamura; Shuzo Matsushita
Journal:  J Virol       Date:  2010-05-26       Impact factor: 5.103

3.  Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.

Authors:  Junji Shibata; Kazuhisa Yoshimura; Akiko Honda; Atsushi Koito; Toshio Murakami; Shuzo Matsushita
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

4.  Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins.

Authors:  Milloni B Patel; Noah G Hoffman; Ronald Swanstrom
Journal:  J Virol       Date:  2007-11-14       Impact factor: 5.103

5.  V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.

Authors:  Reem Berro; Per Johan Klasse; Martin R Jakobsen; Paul R Gorry; John P Moore; Rogier W Sanders
Journal:  Virology       Date:  2012-03-16       Impact factor: 3.616

6.  Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.

Authors:  Timothy J Henrich; Athe M N Tsibris; Nicolas R P Lewine; Ioannis Konstantinidis; Kay E Leopold; Manish Sagar; Daniel R Kuritzkes
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12       Impact factor: 3.731

7.  Existence of Replication-Competent Minor Variants with Different Coreceptor Usage in Plasma from HIV-1-Infected Individuals.

Authors:  Yosuke Maeda; Taichiro Takemura; Takayuki Chikata; Takeo Kuwata; Hiromi Terasawa; Riito Fujimoto; Nozomi Kuse; Tomohiro Akahoshi; Hayato Murakoshi; Giang Van Tran; Yu Zhang; Chau Ha Pham; Anh Hong Quynh Pham; Kazuaki Monde; Tomohiro Sawa; Shuzo Matsushita; Trung Vu Nguyen; Kinh Van Nguyen; Futoshi Hasebe; Tetsu Yamashiro; Masafumi Takiguchi
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

8.  Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.

Authors:  Shigeyoshi Harada; Kazuhisa Yoshimura; Aki Yamaguchi; Samatchaya Boonchawalit; Keisuke Yusa; Shuzo Matsushita
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891

9.  Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies.

Authors:  Takeo Kuwata; Ikumi Enomoto; Masanori Baba; Shuzo Matsushita
Journal:  Antimicrob Agents Chemother       Date:  2015-11-02       Impact factor: 5.191

10.  Conformational epitope consisting of the V3 and V4 loops as a target for potent and broad neutralization of simian immunodeficiency viruses.

Authors:  Takeo Kuwata; Kaori Takaki; Kazuhisa Yoshimura; Ikumi Enomoto; Fan Wu; Ilnour Ourmanov; Vanessa M Hirsch; Masaru Yokoyama; Hironori Sato; Shuzo Matsushita
Journal:  J Virol       Date:  2013-03-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.